EMD Serono Tops Off Research Facility

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, marked the expansion of its research facility in Billerica with a topping off ceremony. “Our vision is clear: to discover new treatments for unmet medical needs,” said Fereydoun Firouz, President and CEO of EMD Serono, Inc. “By increasing our innovative research capabilities through this ambitious expansion project, EMD Serono will further strengthen its ability to drive significant scientific advances in neurodegenerative diseases, cancer and fertility. Our commitment to the growth and future of EMD Serono is steadfast, and to the life sciences industry as a whole in the state of Massachusetts.”

Billerica, MA – EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, marked the expansion of its research facility in Billerica with a topping off ceremony. “Our vision is clear: to discover new treatments for unmet medical needs,” said Fereydoun Firouz, President and CEO of EMD Serono, Inc. “By increasing our innovative research capabilities through this ambitious expansion project, EMD Serono will further strengthen its ability to drive significant scientific advances in neurodegenerative diseases, cancer and fertility. Our commitment to the growth and future of EMD Serono is steadfast, and to the life sciences industry as a whole in the state of Massachusetts.” The expansion of the Billerica facility, announced in 2008, represents a $65 million investment. Construction of the new 140,000sf facility is expected to be complete in late 2010. The new facility will support the company’s commitment to developing a state-of-the-art center of excellence focused on discovering innovative treatments for unmet medical needs. The new site will accommodate approximately 200 scientists with expertise in cancer biology, cancer immunotherapy, oncogene signaling, medicinal chemistry, molecular modeling, protein engineering, therapeutic antibodies and manufacturing cell lines across the core therapeutic areas of neurodegenerative diseases, cancer and fertility. Once complete, the new research facility will accommodate over 115,000sf of lab and office space, consisting of: 25,000sf of chemistry and screening labs; 25,000sf of biology and cell culture labs; 22,000sf of general lab support space; 20,000sf of office and conference rooms and 23,000sf of mechanical space. In addition, 25,000sf will be the central node space, which will consist of the reception area, cafeteria/auditorium, fitness center and offices and conference rooms. In total, the completed EMD Serono research facility will be 140,000sf. EMD Serono is currently working for LEED certification within the following categories: indoor environment quality, sustainable sites, water efficiency, energy and atmosphere and materials and resources.